From the Food and Drug Administration.
Nightingale
S L
SL
Office of Health Affairs, FDA, Rockville, MD 20857.
D003723:Dental Amalgam / Q000592:standards*; D004345:Drug Industry; D005776:Gaucher Disease / Q000188:drug therapy*; D005962:Glucosylceramidase / Q000627:therapeutic use*; D006526:Hepatitis C / Q000628:therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D007391:International Cooperation; D011994:Recombinant Proteins; D014481:United States; D014486:United States Food and Drug Administration
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; C070292:alglucerase; D003723:Dental Amalgam; D005962:Glucosylceramidase